Drug Design, Development and Therapy (Nov 2023)
Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib
Abstract
Shiting Li, Hongqin Wang Department of Pharmacy, Inner Mongolia Baogang Hospital, Baotou City, Inner, Mongolia, People’s Republic of ChinaCorrespondence: Hongqin Wang, Department of Pharmacy, Inner Mongolia Baogang Hospital, No. 20, Shaoxian Road, Kun District, Baotou City, Inner, Mongolia, 014010, People’s Republic of China, Tel +86-472-5992956, Email [email protected]: Anti-angiogenesis therapy plays a vital role in the treatment of tumors, with anlotinib as its representative targeted drug. Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) with inhibitory effects on tumor growth tumor angiogenesis. In Phase III clinical trials, anlotinib demonstrated better overall survival and progression-free survival than placebo in patients with advanced non-small cell lung cancer (NSCLC), and was approved for the first time as a third-line treatment for refractory advanced NSCLC. Going far beyond that, anlotinib has shown encouraging results in a variety of malignancies, including medullary thyroid carcinoma, renal cell carcinoma, gastric cancer and esophageal squamous cell carcinoma. Nevertheless, anlotinib has been subject to some controversy in terms of adverse events due to its widespread use. In this review, the mechanism of action, pharmacokinetic characteristics, adverse reactions in clinical use and management of anlotinib were summarized. Keywords: anlotinib, anti-angiogenesis, non-small cell lung cancer, anti-cancer mechanism, adverse drug reaction
